Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
Stephanie Si,1,2 David T Teachey1,2 1Children’s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA; 2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USACorrespondence: Stephanie SiUniversity of Hawai’i Cancer...
Main Authors: | Si S, Teachey DT |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/spotlight-on-tocilizumab-in-the-treatment-of-car-t-cell-induced-cytoki-peer-reviewed-article-TCRM |
Similar Items
-
Cytokine Release Syndrome: An Overview on its Features and Management
by: Shailza Shreshtha, et al.
Published: (2019-03-01) -
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
by: Tom van Kraaij, et al.
Published: (2020-04-01) -
Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
by: Sadettin Uslu
Published: (2020-05-01) -
Cytokine Release Syndrome: Current Perspectives
by: Murthy H, et al.
Published: (2019-10-01) -
Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
by: Monica S. Thakar, et al.
Published: (2020-01-01)